Yaël P. Mossé

13.0k citations

96 papers · 4.6k indexed · 1 hit paper · h-index 35

Neurology top 0.2%
Molecular Biology top 5%
Cancer Research top 1%
Oncology top 2%
Pulmonary and Respiratory Medicine top 5%

Co-authors: John M. Maris Edward F. Attiyeh Kristina A. Cole Sharon J. Diskin Brenda J. Weigel Susan M. Blaney Andrew Wood Garrett M. Brodeur
Topics: Neuroblastoma Research and Treatments (83 papers)Cancer, Hypoxia, and Metabolism (35 papers)Cancer therapeutics and mechanisms (30 papers)
Cited by: Neurology Cancer Research Oncology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Journal of Clinical Oncology
Partner nations: United States Canada United Kingdom

In The Last Decade

Yaël P. Mossé

93 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

2013 477 citations Yaël P. Mossé, Megan S. Lim et al. profile →

Peers

Countries citing papers authored by Yaël P. Mossé

Since Specialization

Citations

This map shows the geographic impact of Yaël P. Mossé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaël P. Mossé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaël P. Mossé more than expected).

Fields of papers citing papers by Yaël P. Mossé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaël P. Mossé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaël P. Mossé. The network helps show where Yaël P. Mossé may publish in the future.

Co-authorship network of co-authors of Yaël P. Mossé

This figure shows the co-authorship network connecting the top 25 collaborators of Yaël P. Mossé. A scholar is included among the top collaborators of Yaël P. Mossé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaël P. Mossé. Yaël P. Mossé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study 2025 ·Journal of Clinical Oncology ·Esther R. Berko,Arlene Naranjo,(unknown),Samantha N. McNulty,Kateryna Krytska,Todd E. Druley,Kristin Zelley,(unknown),Lulu Chen,(unknown),Meredith S. Irwin,Rochelle Bagatell,John M. Maris,C. Patrick Reynolds,Steven G. DuBois,Julie R. Park,Yaël P. Mossé	1
2	Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets 2025 ·Neuro-Oncology ·Nathan M. Kendsersky,(unknown),Nathaniel W. Mabe,Alvin Farrel,(unknown),(unknown),David Groff,Adam J. Wolpaw,(unknown),Francesca Zammarchi,Patrick H. van Berkel,Chi V. Dang,Yaël P. Mossé,Kimberly Stegmaier,John M. Maris	1
3	Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma 2025 ·Molecular Cancer Therapeutics ·Smita Matkar,Michael P. East,Timothy J. Stuhlmiller,(unknown),Alvin Farrel,Steven Pastor,(unknown),(unknown),(unknown),Esther R. Berko,(unknown),Kateryna Krytska,Khushbu Patel,Jo Lynne Rokita,(unknown),John M. Maris,Gary L. Johnson,Yaël P. Mossé	2
4	Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma 2022 ·Cancer Research Communications ·Kateryna Krytska,(unknown),Jennifer Pogoriler,Daniel Martínez,Komal S. Rathi,Alvin Farrel,Esther R. Berko,(unknown),(unknown),Nathan M. Kendsersky,Stephen W. Erickson,Beverly A. Teicher,Kumiko Isse,Laura R. Saunders,Malcolm A. Smith,John M. Maris,Yaël P. Mossé	5
5	Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma 2021 ·Molecular Cancer Therapeutics ·(unknown),Kateryna Krytska,Timothy L. Lochmann,Renata Sano,(unknown),(unknown),Qasim A. Khan,(unknown),(unknown),Jinyang Cai,Sheeba Jacob,Richard Kurupi,Bin Hu,Mikhail G. Dozmorov,Patricia Greninger,Andrew J. Souers,Cyril H. Benes,Yaël P. Mossé,Anthony C. Faber	13
6	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) 2021 ·Clinical Cancer Research ·Jennifer H. Foster,Stephan D. Voss,David Hall,Charles G. Minard,Frank M. Balis,Keith D. Wilner,Stacey L. Berg,Elizabeth Fox,Peter C. Adamson,Susan M. Blaney,Brenda J. Weigel,Yaël P. Mossé	61
7	A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study 2021 ·Pediatric Blood & Cancer ·Brian Weiss,Gregory A. Yanik,Arlene Naranjo,Fan F. Zhang,Wendy Fitzgerald,Barry L. Shulkin,Marguerite T. Parisi,Heidi V. Russell,Stephan A. Grupp,Luke Pater,Peter Mattei,Yaël P. Mossé,Hollie Lai,Jason A. Jarzembowski,Hiroyuki Shimada,Judith G. Villablanca,Roger Giller,Rochelle Bagatell,Julie R. Park,Katherine K. Matthay	23
8	Advances and Challenges in Pediatric and Childhood Cancers 2020 ·Cancer Cell ·Cynthia Hawkins,Stefan M. Pfister,David Jones,Nirali N. Shah,Richard J. Gilbertson,E. Alejandro Sweet‐Cordero,Michael A. Dyer,Yaël P. Mossé,Michelle Haber,Steven G. DuBois	2
9	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212) 2020 ·Cancer Chemotherapy and Pharmacology ·Emily Greengard,Yaël P. Mossé,Xiaowei Liu,Charles G. Minard,Joel M. Reid,Stephan D. Voss,Keith D. Wilner,Elizabeth Fox,Frank M. Balis,Susan M. Blaney,Peter C. Adamson,Brenda J. Weigel	18
10	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) 2019 ·Clinical Cancer Research ·Yaël P. Mossé,Elizabeth Fox,David T. Teachey,Joel M. Reid,Stephanie L. Safgren,Hernán Carol,Richard B. Lock,Peter J. Houghton,Malcolm A. Smith,David Hall,Donald A. Barkauskas,Mark Krailo,Stephan D. Voss,Stacey L. Berg,Susan M. Blaney,Brenda J. Weigel	79
11	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study 2017 ·Journal of Clinical Oncology ·Yaël P. Mossé,Stephan D. Voss,Megan S. Lim,Delphine Rolland,Charles G. Minard,Elizabeth Fox,Peter C. Adamson,Keith D. Wilner,Susan M. Blaney,Brenda J. Weigel	247
12	Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma 2016 ·Clinical Cancer Research ·Andrew Wood,Kateryna Krytska,Hannah T. Ryles,Nicole R. Infarinato,Renata Sano,(unknown),Lori S. Hart,Frederick J. King,Timothy R. Smith,Edward Ainscow,Kathryn B. Grandinetti,Tove Tuntland,Sunkyu Kim,Giordano Caponigro,You He,Shiva Krupa,Nanxin Li,Jennifer L. Harris,Yaël P. Mossé	67
13	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma 2015 ·Cancer Discovery ·Nicole R. Infarinato,Jin H. Park,Kateryna Krytska,Hannah T. Ryles,Renata Sano,(unknown),Yimei Li,Helen Y. Zou,Nathan V. Lee,Tod Smeal,Mark A. Lemmon,Yaël P. Mossé	116
14	Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma 2015 ·Clinical Cancer Research ·Kateryna Krytska,Hannah T. Ryles,Renata Sano,Pichai Raman,Nicole R. Infarinato,(unknown),Monish Ram Makena,Michael M. Song,C. Patrick Reynolds,Yaël P. Mossé	76
15	Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma 2015 ·British Journal of Cancer ·Steven G. DuBois,Steven L. Allen,(unknown),Joan F. Hilton,(unknown),R A Hawkins,Jesse Courtier,Yaël P. Mossé,Katherine K. Matthay	44
16	Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy 2009 ·Genome Research ·Edward F. Attiyeh,Sharon J. Diskin,Marc A. Attiyeh,Yaël P. Mossé,Cuiping Hou,Eric M. Jackson,Cecilia Kim,Joseph Glessner,Håkon Håkonarson,Jaclyn A. Biegel,John M. Maris	66
17	A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene 2008 ·Molecular Cancer Research ·Kristina A. Cole,Edward F. Attiyeh,Yaël P. Mossé,Michael P. LaQuaglia,Sharon J. Diskin,Garrett M. Brodeur,John M. Maris	242
18	Cortical Processing of Respiratory Occlusion Stimuli in Children with Central Hypoventilation Syndrome 2008 ·American Journal of Respiratory and Critical Care Medicine ·Jingtao Huang,Carole L. Marcus,(unknown),Michael S. Schwartz,(unknown),John Samuel,Howard B. Panitch,Ruth Bradford,Yaël P. Mossé,John M. Maris,Ian M. Colrain	12
19	The microRNA miR-34a is a candidate 1p36 tumor suppressor gene in neuroblastoma 2007 ·Cancer Research ·Kristina A. Cole,Edward F. Attiyeh,Yaël P. Mossé,Sharon J. Diskin,Garrett M. Brodeur,John M. Maris	1
20	Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era 2005 ·Cancer Letters ·Yaël P. Mossé,Joel Greshock,Barbara L. Weber,John M. Maris	13

About Yaël P. Mossé

Yaël P. Mossé is a scholar working on Neurology, Cancer Research and Oncology, having authored 96 papers that have together received 4.6k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (83 papers), Cancer, Hypoxia, and Metabolism (35 papers) and Cancer therapeutics and mechanisms (30 papers). The work is most often cited by research in Neurology (2.7k citations), Cancer Research (1.7k citations) and Oncology (1.3k citations). Yaël P. Mossé has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John M. Maris, Edward F. Attiyeh, Kristina A. Cole, Sharon J. Diskin, Brenda J. Weigel, Susan M. Blaney, Andrew Wood, Garrett M. Brodeur, Peter C. Adamson and Erica L. Carpenter. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact